WHIM syndrome 1
MONDO:8000006A congenital autosomal dominant immune deficiency characterized by abnormal retention of mature neutrophils in the bone marrow (myelokathexis) and occasional hypogammaglobulinemia, associated with an increased risk for bacterial infections and a susceptibility to human papillomavirus (HPV) induced lesions (cutaneous warts, genital dysplasia and invasive mucosal carcinoma).
Also known as: WHIM syndrome, WHIM Syndrome, WHIMS, WILM, Warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, Warts-hypogammaglobulinemia-infections-myelokathexis syndrome, Warts-infections-leukopenia-myelokatexis syndrome, myelokathexis, isolated
4 clinical trials for this condition and its sub-types, 4 tagged with WHIM syndrome 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a stem cell drug tame rare immune disease?
Disease control CompletedThis early-phase study tests whether Mozobil, a drug already used to boost stem cells for transplants, can safely raise white blood cell counts in people with WHIMS. WHIMS is a rare genetic condition that traps infection-fighting cells in the bone marrow, leading to frequent infe…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental drug aims to boost immunity in rare WHIM syndrome
Disease control CompletedThis phase 3 trial tests whether mavorixafor can raise neutrophil levels in people with WHIM syndrome, a rare genetic condition that weakens the immune system. Participants receive either mavorixafor or a placebo to see if the drug helps maintain infection-fighting white blood ce…
Phase 3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Rare disease drug shows promise in reducing infections
Disease control CompletedThis study tested two drugs, plerixafor and G-CSF, in 20 people with WHIM syndrome, a rare genetic condition that causes frequent infections and warts. Participants received each drug for a year and tracked their infections. The goal was to see which drug better reduced infection…
Phase 2/3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC